ForPatients
by Roche

Huntington Disease (HD)

Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

Trial Status	Trial Runs In	Trial Identifier
Recruiting	7 Countries	NCT06667414 WE45491

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Official Title:

Frequency of Selected Single Nucleotide Polymorphisms in Phase With the Mutant and Wild-Type HTT Alleles in Huntington Disease Gene Expansion Carriers

Trial Summary:

For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their demographics, including sex, age, race and ethnicity, and their medical and medication history. At the end of the visit, a blood sample will be drawn to allow testing with a sequencing assay that is specifically designed for phasing single nucleotide polymorphisms (SNPs) on the wild-type Huntington (wtHTT) and mutant Huntington (mHTT) alleles.

Hoffmann-La Roche	N/A
Sponsor	Phase

NCT06667414 WE45491
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	#25 Years & # 60 Years	No

Inclusion Criteria:

- Have signed the Informed Consent Form (ICF)
- Aged 25 to 60 years, inclusive, at the time of signing the ICF

- Confirmation of Huntington Disease (HD) gene expansion mutation carrier status
- Confirmation of Total Functional Capacity (TFC) #9 and Total Motor Score (TMS) >6 within 12 months prior to signing the ICF
- Ability to tolerate blood draws

Exclusion Criteria:

- None